Scientists say treatments to muzzle faulty genes are making some headway.
Researchers propose the same phenomenon explains poor clinical trial results.
John Hardy wins the Breakthrough Prize for his seminal research into the genetic underpinnings of Alzheimer’s disease.
Scientists at SfN offer alternate views of Bin1 biology.
Scientists start to unravel role played by genetic risk variants.
Two drugs that boost α-synuclein clearance have passed Phase 1 safety benchmarks, and a stem cell strategy is poised to enter trials, reported scientists at SfN 2015.
The protein creeps up in the cerebrospinal fluid as the disease worsens.
More-active animals maintained healthier neurovascular systems if they carried the ApoE gene.
Researchers at SfN 2015 outlined perinatal treatments that rescued cognition in mouse models of the disease.
The RNA-binding protein hnRNP A3 can help rid a cell of the repeat RNAs, but the RNAs interfere with its nuclear localization.
Research presented at SfN strengthens the case that microglia gorge on synapses in some neurodegenerative and neurodevelopmental disorders.
Researchers think montelukast could hold promise for people with neurodegenerative disease.
C9ORF72 Mice Point to Gain of Toxic Function in ALS, FTD Does C9ORF72 Repeat RNA Promote Protein Phase Transitions? RNA Regulator Locked Out of Nucleus by C9ORF72 Repeats Listen Up, Gene Silencing Strikes a Chord at RNA Meeting Stressed Out: RNA-binding ...
The ALS-linked RNA may convert free-floating proteins to liquid phase droplets.
Phenotypes vary depending on the partial or full-length nature of the C9ORF72 transgene.
No filters selected